Alain Labelle

2.8k total citations
82 papers, 2.1k citations indexed

About

Alain Labelle is a scholar working on Psychiatry and Mental health, Cognitive Neuroscience and Molecular Biology. According to data from OpenAlex, Alain Labelle has authored 82 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Psychiatry and Mental health, 29 papers in Cognitive Neuroscience and 14 papers in Molecular Biology. Recurrent topics in Alain Labelle's work include Schizophrenia research and treatment (39 papers), Neuroscience and Music Perception (17 papers) and Mental Health and Psychiatry (11 papers). Alain Labelle is often cited by papers focused on Schizophrenia research and treatment (39 papers), Neuroscience and Music Perception (17 papers) and Mental Health and Psychiatry (11 papers). Alain Labelle collaborates with scholars based in Canada, United States and France. Alain Labelle's co-authors include Verner Knott, Derek J. Fisher, Scot E. Purdon, B. Jones, Dylan Smith, Ridha Joober, Samarthji Lal, Guy A. Rouleau, Chawki Benkelfat and Ashok Malla and has published in prestigious journals such as SHILAP Revista de lepidopterología, American Journal of Psychiatry and Biological Psychiatry.

In The Last Decade

Alain Labelle

81 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alain Labelle Canada 30 1.0k 845 331 312 283 82 2.1k
Harald Scherk Germany 26 1.3k 1.2× 705 0.8× 331 1.0× 298 1.0× 193 0.7× 51 2.2k
Joanne Wojcik United States 23 946 0.9× 1.3k 1.5× 302 0.9× 308 1.0× 204 0.7× 50 2.7k
Hélio Elkis Brazil 26 1.4k 1.3× 574 0.7× 246 0.7× 505 1.6× 189 0.7× 105 2.2k
H.‐J. Möller Germany 27 1.0k 1.0× 671 0.8× 228 0.7× 281 0.9× 276 1.0× 55 2.6k
Hans‐Jürgen Möller Germany 28 2.0k 1.9× 742 0.9× 310 0.9× 420 1.3× 368 1.3× 42 3.2k
Henry Silver Israel 26 1.3k 1.3× 593 0.7× 443 1.3× 458 1.5× 272 1.0× 82 2.3k
Lutz Schmidt Germany 27 1.0k 1.0× 467 0.6× 594 1.8× 397 1.3× 295 1.0× 66 2.4k
Fernando Caravaggio Canada 26 1.0k 1.0× 628 0.7× 549 1.7× 224 0.7× 334 1.2× 98 2.3k
Pesach Lichtenberg Israel 21 616 0.6× 523 0.6× 337 1.0× 368 1.2× 197 0.7× 74 1.8k
Jogin H. Thakore United Kingdom 25 1.4k 1.4× 428 0.5× 209 0.6× 216 0.7× 283 1.0× 61 3.0k

Countries citing papers authored by Alain Labelle

Since Specialization
Citations

This map shows the geographic impact of Alain Labelle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alain Labelle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alain Labelle more than expected).

Fields of papers citing papers by Alain Labelle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alain Labelle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alain Labelle. The network helps show where Alain Labelle may publish in the future.

Co-authorship network of co-authors of Alain Labelle

This figure shows the co-authorship network connecting the top 25 collaborators of Alain Labelle. A scholar is included among the top collaborators of Alain Labelle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alain Labelle. Alain Labelle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Labelle, Alain, et al.. (2021). The acute dose and baseline amplitude-dependent effects of CDP-choline on deviance detection (MMN) in chronic schizophrenia: A pilot study.. Experimental and Clinical Psychopharmacology. 30(2). 235–248. 2 indexed citations
2.
Knott, Verner, et al.. (2020). Interaction of Background Noise and Auditory Hallucinations on Phonemic Mismatch Negativity (MMN) and P3a Processing in Schizophrenia. Frontiers in Psychiatry. 11. 540738–540738. 8 indexed citations
3.
Choueiry, Joëlle, Dhrasti Shah, Dylan Smith, et al.. (2019). Combining CDP-choline and galantamine, an optimized α7 nicotinic strategy, to ameliorate sensory gating to speech stimuli in schizophrenia. International Journal of Psychophysiology. 145. 70–82. 17 indexed citations
4.
Bourget, Dominique, et al.. (2018). Sex Chromosome Abnormality and Sexual Behaviour: Selective TreatmentApproaches - A Case Series of 5 Klinefelter’s Men. 7(8). 586–594. 1 indexed citations
5.
Fisher, Derek J., Dylan Smith, Alain Labelle, & Verner Knott. (2014). Attenuation of mismatch negativity (MMN) and novelty P300 in schizophrenia patients with auditory hallucinations experiencing acute exacerbation of illness. Biological Psychology. 100. 43–49. 35 indexed citations
6.
Labelle, Alain, et al.. (2010). Acute Nicotine Alteration of Sensory Memory Impairment in Smokers With Schizophrenia. Journal of Clinical Psychopharmacology. 30(5). 541–548. 50 indexed citations
7.
Fisher, Derek J., Alain Labelle, & Verner Knott. (2010). Auditory hallucinations and the P3a: Attention-switching to speech in schizophrenia. Biological Psychology. 85(3). 417–423. 28 indexed citations
8.
Joober, Ridha, Guy A. Rouleau, Samarthji Lal, et al.. (2005). Increased prevalence of schizophrenia spectrum disorders in relatives of neuroleptic-nonresponsive schizophrenic patients. Schizophrenia Research. 77(1). 35–41. 26 indexed citations
9.
Kutcher, Stan, Sarah J. Brooks, David M. Gardner, et al.. (2005). Expert Canadian consensus suggestions on the rational, clinical use of ziprasidone in the treatment of schizophrenia and related psychotic disorders. Neuropsychiatric Disease and Treatment. 1(2). 89–108. 9 indexed citations
10.
Xiong, Lan, Guy A. Rouleau, Lynn E. DeLisi, et al.. (2004). CAA insertion polymorphism in the 3′UTR of Nogo gene on 2p14 is not associated with schizophrenia. Molecular Brain Research. 133(1). 153–156. 10 indexed citations
11.
Labelle, Alain, et al.. (2002). Switching Outpatients With Schizophrenia and Related Disorders on Long-Acting Injectable Antipsychotics to Olanzapine: An Open-Label Naturalistic Pilot Study. Journal of Clinical Psychopharmacology. 22(6). 545–553. 7 indexed citations
12.
Yamamoto, Kenji, Joseph F. Cubells, Joel Gelernter, et al.. (2002). Dopamine Beta‐Hydroxylase (DBH) gene and schizophrenia phenotypic variability: A genetic association study. American Journal of Medical Genetics Part B Neuropsychiatric Genetics. 117B(1). 33–38. 36 indexed citations
13.
Knott, Verner, Alain Labelle, B. Jones, & Colleen Mahoney. (2002). EEG coherence following acute and chronic clozapine in treatment-resistant schizophrenics.. Experimental and Clinical Psychopharmacology. 10(4). 435–444. 18 indexed citations
14.
Purdon, Scot E., Alain Labelle, & L. Boulay. (2001). Neuropsychological change in schizophrenia after 6 weeks of clozapine. Schizophrenia Research. 48(1). 57–67. 40 indexed citations
15.
Joober, Ridha, Chawki Benkelfat, Katéri Brisebois, et al.. (1999). T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability.. PubMed Central. 24(2). 141–6. 98 indexed citations
16.
Knott, Verner, et al.. (1999). Event-related potentials in schizophrenic patients during a degraded stimulus version of the visual continuous performance task. Schizophrenia Research. 35(3). 263–278. 21 indexed citations
17.
Lapierre, Y.D., A. George Awad, B. Jones, et al.. (1999). The treatment of negative symptoms: a clinical and methodological study. International Clinical Psychopharmacology. 14(2). 101–112. 8 indexed citations
18.
Alda, Martin, B. Ahrens, M Dvořáková, et al.. (1996). Age of onset in familial and sporadic schizoph4.4.renia. Acta Psychiatrica Scandinavica. 93(6). 447–450. 54 indexed citations
19.
Labelle, Alain & Y.D. Lapierre. (1993). Anxiety disorders. Part 2: Pharmacotherapy with benzodiazepines.. PubMed. 39. 2205–8; 2211. 2 indexed citations
20.
Labelle, Alain & Y.D. Lapierre. (1991). Keratodermia: side effects of lithium.. PubMed. 11(2). 149–50. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Harald Scherk Breakdown of academic impact, for papers by Joanne Wojcik Breakdown of academic impact, for papers by Hélio Elkis Breakdown of academic impact, for papers by H.‐J. Möller Breakdown of academic impact, for papers by Hans‐Jürgen Möller Breakdown of academic impact, for papers by Henry Silver Breakdown of academic impact, for papers by Lutz Schmidt Breakdown of academic impact, for papers by Fernando Caravaggio Breakdown of academic impact, for papers by Pesach Lichtenberg Breakdown of academic impact, for papers by Jogin H. Thakore
Rankless by CCL
2026